120 related articles for article (PubMed ID: 6523433)
21. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacology of hirulog-like peptide.
Tang XF; Qian J; Wan DJ; Zhu JH; Gao PJ; Zhu DL; Shen GX
J Cardiovasc Pharmacol; 2007 Oct; 50(4):406-10. PubMed ID: 18049308
[TBL] [Abstract][Full Text] [Related]
23. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Kaiser B; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
[TBL] [Abstract][Full Text] [Related]
25. Quantitative determination of hirudin in blood and body fluids.
Nowak G; Bucha E
Semin Thromb Hemost; 1996; 22(2):197-202. PubMed ID: 8807717
[TBL] [Abstract][Full Text] [Related]
26. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
27. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
28. Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.
Johnson FL; Boyer JL; Leese PT; Crean C; Krishnamoorthy R; Durham T; Fox AW; Kellerman DJ
Platelets; 2007 Aug; 18(5):346-56. PubMed ID: 17654304
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.
Markwardt F; Hauptmann J; Nowak G; Klessen C; Walsmann P
Thromb Haemost; 1982 Jun; 47(3):226-9. PubMed ID: 7112494
[TBL] [Abstract][Full Text] [Related]
30. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
[TBL] [Abstract][Full Text] [Related]
31. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
[TBL] [Abstract][Full Text] [Related]
32. The effect of different anticoagulants on thrombin generation.
Petros S; Siegemund T; Siegemund A; Engelmann L
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):131-7. PubMed ID: 16479195
[TBL] [Abstract][Full Text] [Related]
33. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding.
Schols SE; van der Meijden PE; van Oerle R; Curvers J; Heemskerk JW; van Pampus EC
Thromb Haemost; 2008 Jan; 99(1):64-70. PubMed ID: 18217136
[TBL] [Abstract][Full Text] [Related]
34. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
[TBL] [Abstract][Full Text] [Related]
35. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
Rübsamen K; Hornberger W
Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
[TBL] [Abstract][Full Text] [Related]
36. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
[TBL] [Abstract][Full Text] [Related]
37. Hemostatic defect in baboons autotransfused treated plasma to simulate shed blood.
Valeri CR; Morse DS; Ragno G; Dennis RC
J Card Surg; 2006; 21(6):565-71. PubMed ID: 17073954
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs.
Abendschein DR; Recchia D; Meng YY; Oltrona L; Wickline SA; Eisenberg PR
J Am Coll Cardiol; 1996 Dec; 28(7):1849-55. PubMed ID: 8962575
[TBL] [Abstract][Full Text] [Related]
39. Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism.
Bridey F; Dreyfus M; Parent F; Bros A; Fischer AM; Camez A; Simonneau G; Duroux P; Meyer D
Am J Hematol; 1995 May; 49(1):67-72. PubMed ID: 7741141
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.
Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G
Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
